Bisoprolol detailed information: Difference between revisions

Revision as of 05:44, 4 February 2014

Bisoprolol
ZEBETA^® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Bisoprolol
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2] For patient information about Bisoprolol, click here

Synonyms / Brand Names: Template:ZEBETA

Bisoprolol is a drug belonging to the group of beta blockers, a class of drugs used primarily in cardiovascular diseases. More specifically, it is a selective type β1 adrenergic receptor blocker ^[1].

The mechanism of action of its antihypertensive effects has not been completely established. Factors which may be involved include:

Decreased cardiac output,
Inhibition of renin release by the kidneys,
Diminution of tonic sympathetic outflow from the vasomotor centers in the brain.

@@ Line 15: / Line 15: @@
 '''| [[Bisoprolol indications and usage|Indications and Usage]]'''
 '''| [[Bisoprolol dosage and administration|Dosage and Administration]]'''
-'''| [[Bisoprolol dosage forms and strengths|Dosage Forms and Strengths]]'''
 '''| [[Bisoprolol contraindications|Contraindications]]'''
 '''| [[Bisoprolol warnings and precautions|Warnings and Precautions]]'''
@@ Line 32: / Line 31: @@
 ==Mechanism of Action==
+The mechanism of action of its antihypertensive effects has not been completely established. Factors which may be involved include:
+*Decreased cardiac output,
+*Inhibition of renin release by the kidneys,
+*Diminution of tonic sympathetic outflow from the vasomotor centers in the brain.
 ==References==